Literature DB >> 33767315

Value of contrast-enhanced CT texture analysis in predicting IDH mutation status of intrahepatic cholangiocarcinoma.

Yong Zhu1, Yingfan Mao2, Jun Chen3, Yudong Qiu4, Yue Guan5, Zhongqiu Wang6, Jian He7.   

Abstract

To explore the value of contrast-enhanced CT texture analysis in predicting isocitrate dehydrogenase (IDH) mutation status of intrahepatic cholangiocarcinomas (ICCs). Institutional review board approved this study. Contrast-enhanced CT images of 138 ICC patients (21 with IDH mutation and 117 without IDH mutation) were retrospectively reviewed. Texture analysis was performed for each lesion and compared between ICCs with and without IDH mutation. All textural features in each phase and combinations of textural features (p < 0.05) by Mann-Whitney U tests were separately used to train multiple support vector machine (SVM) classifiers. The classification generalizability and performance were evaluated using a tenfold cross-validation scheme. Among plain, arterial phase (AP), portal venous phase (VP), equilibrium phase (EP) and Sig classifiers, VP classifier showed the highest accuracy of 0.863 (sensitivity, 0.727; specificity, 0.885), with a mean area under the receiver operating characteristic curve of 0.813 in predicting IDH mutation in validation cohort. Texture features of CT images in portal venous phase could predict IDH mutation status of ICCs with SVM classifier preoperatively.

Entities:  

Year:  2021        PMID: 33767315     DOI: 10.1038/s41598-021-86497-4

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  38 in total

Review 1.  Cholangiocarcinoma.

Authors:  Shahid A Khan; Howard C Thomas; Brian R Davidson; Simon D Taylor-Robinson
Journal:  Lancet       Date:  2005-10-08       Impact factor: 79.321

2.  [Pathology and urodynamics of megaloureter (author's transl)].

Authors:  S Tokunaka
Journal:  Nihon Hinyokika Gakkai Zasshi       Date:  1980-11

3.  Metabolism unhinged: IDH mutations in cancer.

Authors:  John R Prensner; Arul M Chinnaiyan
Journal:  Nat Med       Date:  2011-03       Impact factor: 87.241

4.  Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas.

Authors:  Yuchen Jiao; Timothy M Pawlik; Robert A Anders; Florin M Selaru; Mirte M Streppel; Donald J Lucas; Noushin Niknafs; Violeta Beleva Guthrie; Anirban Maitra; Pedram Argani; G Johan A Offerhaus; Juan Carlos Roa; Lewis R Roberts; Gregory J Gores; Irinel Popescu; Sorin T Alexandrescu; Simona Dima; Matteo Fassan; Michele Simbolo; Andrea Mafficini; Paola Capelli; Rita T Lawlor; Andrea Ruzzenente; Alfredo Guglielmi; Giampaolo Tortora; Filippo de Braud; Aldo Scarpa; William Jarnagin; David Klimstra; Rachel Karchin; Victor E Velculescu; Ralph H Hruban; Bert Vogelstein; Kenneth W Kinzler; Nickolas Papadopoulos; Laura D Wood
Journal:  Nat Genet       Date:  2013-11-03       Impact factor: 38.330

5.  Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas.

Authors:  P Wang; Q Dong; C Zhang; P-F Kuan; Y Liu; W R Jeck; J B Andersen; W Jiang; G L Savich; T-X Tan; J T Auman; J M Hoskins; A D Misher; C D Moser; S M Yourstone; J W Kim; K Cibulskis; G Getz; H V Hunt; S S Thorgeirsson; L R Roberts; D Ye; K-L Guan; Y Xiong; L-X Qin; D Y Chiang
Journal:  Oncogene       Date:  2012-07-23       Impact factor: 8.756

6.  Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping.

Authors:  Darrell R Borger; Kenneth K Tanabe; Kenneth C Fan; Hector U Lopez; Valeria R Fantin; Kimberly S Straley; David P Schenkein; Aram F Hezel; Marek Ancukiewicz; Hannah M Liebman; Eunice L Kwak; Jeffrey W Clark; David P Ryan; Vikram Deshpande; Dora Dias-Santagata; Leif W Ellisen; Andrew X Zhu; A John Iafrate
Journal:  Oncologist       Date:  2011-12-16       Impact factor: 5.837

7.  IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.

Authors:  Guido Marcucci; Kati Maharry; Yue-Zhong Wu; Michael D Radmacher; Krzysztof Mrózek; Dean Margeson; Kelsi B Holland; Susan P Whitman; Heiko Becker; Sebastian Schwind; Klaus H Metzeler; Bayard L Powell; Thomas H Carter; Jonathan E Kolitz; Meir Wetzler; Andrew J Carroll; Maria R Baer; Michael A Caligiuri; Richard A Larson; Clara D Bloomfield
Journal:  J Clin Oncol       Date:  2010-04-05       Impact factor: 50.717

8.  Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases.

Authors:  Wei Xu; Hui Yang; Ying Liu; Ying Yang; Ping Wang; Se-Hee Kim; Shinsuke Ito; Chen Yang; Pu Wang; Meng-Tao Xiao; Li-xia Liu; Wen-qing Jiang; Jing Liu; Jin-ye Zhang; Bin Wang; Stephen Frye; Yi Zhang; Yan-hui Xu; Qun-ying Lei; Kun-Liang Guan; Shi-min Zhao; Yue Xiong
Journal:  Cancer Cell       Date:  2011-01-18       Impact factor: 38.585

9.  Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation.

Authors:  Maria E Figueroa; Omar Abdel-Wahab; Chao Lu; Patrick S Ward; Jay Patel; Alan Shih; Yushan Li; Neha Bhagwat; Aparna Vasanthakumar; Hugo F Fernandez; Martin S Tallman; Zhuoxin Sun; Kristy Wolniak; Justine K Peeters; Wei Liu; Sung E Choe; Valeria R Fantin; Elisabeth Paietta; Bob Löwenberg; Jonathan D Licht; Lucy A Godley; Ruud Delwel; Peter J M Valk; Craig B Thompson; Ross L Levine; Ari Melnick
Journal:  Cancer Cell       Date:  2010-12-09       Impact factor: 38.585

10.  IDH1 and IDH2 mutations in gliomas.

Authors:  Hai Yan; D Williams Parsons; Genglin Jin; Roger McLendon; B Ahmed Rasheed; Weishi Yuan; Ivan Kos; Ines Batinic-Haberle; Siân Jones; Gregory J Riggins; Henry Friedman; Allan Friedman; David Reardon; James Herndon; Kenneth W Kinzler; Victor E Velculescu; Bert Vogelstein; Darell D Bigner
Journal:  N Engl J Med       Date:  2009-02-19       Impact factor: 176.079

View more
  2 in total

Review 1.  Radiomics of Biliary Tumors: A Systematic Review of Current Evidence.

Authors:  Francesco Fiz; Visala S Jayakody Arachchige; Matteo Gionso; Ilaria Pecorella; Apoorva Selvam; Dakota Russell Wheeler; Martina Sollini; Luca Viganò
Journal:  Diagnostics (Basel)       Date:  2022-03-28

2.  Radiomics-based model for predicting early recurrence of intrahepatic mass-forming cholangiocarcinoma after curative tumor resection.

Authors:  Yong Zhu; Yingfan Mao; Jun Chen; Yudong Qiu; Yue Guan; Zhongqiu Wang; Jian He
Journal:  Sci Rep       Date:  2021-09-15       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.